INM
InMed Pharmaceuticals Inc.Company with tickers: INM
CIK
1728328
CUSIP
457637700
Shares Outstanding
3,314,063
Website
https://www.inmedpharma.com
Investor Relations
https://www.inmedpharma.com/investors/
13F Activity (30d)
3 filings
3 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $2,839,521 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Research & Development | $1,022,630 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Operating Income | — | ||||
| Net Income | $-2,966,336 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| EPS (Basic) | $-0.73 | USD/shares | 2026-03-31 | 10-Q | 2026-05-06 |
| EPS (Diluted) | $-0.73 | USD/shares | 2026-03-31 | 10-Q | 2026-05-06 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Segment (USD)
| Component | 2022-06-30 | 2023-06-30 |
|---|---|---|
| Bay Medica | $1,089,435 | $4,135,561 |